

Zantel Cat and Dog Tablets

Authorised

- Praziquantel
- Fenbendazole

Product identification

Medicine name:

Zantel Cat and Dog Tablets

Active substance:

Praziquantel

Fenbendazole

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Praziquantel

50.00 milligram(s) / 1.00 Tablet

Fenbendazole

500.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP52AA51

QP52AC13

Legal status of supply:

Veterinary medicinal product not subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Ireland

Package description:

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 120 tablets.Strips: 120 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 100 tablets.Strips: 100 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 60 tablets.Strips: 60 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 50 tablets.Strips: 50 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 48 tablets.Strips: 48 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 30 tablets.Strips: 30 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 24 tablets.Strips: 24 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 20 tablets.Strips: 20 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 12 tablets.Strips: 12 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 10 tablets.Strips: 10 tablets

2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 8 tablets.Strips: 8 tablets
2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 4 tablets.Strips: 4 tablets
2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 3 tablets.Strips: 3 tablets
2. 30µ aluminium foil coated with 35 gsm extruded polythene.3. Foil blisters (aluminium/aluminium).Blisters: 2 tablets.Strips: 2 tablets
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 120 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 100 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 96 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 60 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 50 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 30 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 24 tablets.
1. White high density polyethylene (HDPE) containers with a white polypropylene child resistant tamper evident cap.Containers: 20 tablets.
2. 30µ aluminium foil coated with 35 gsm extruded polythene. 3. Foil blisters (aluminium/aluminium). Blisters: 96 tablets. Strips: 96 tablets
-

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Complete application (stand-alone) - Council Directive 81/851/EEC

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:

4/05/2001

Manufacturing sites for batch release:

Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:

Health Products Regulatory Authority

Authorisation number:

VPA10987/052/001

Date of authorisation status change:

4/05/2001

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics